SciVision Biotech (Taiwan) Performance
| 1786 Stock | TWD 94.30 1.40 1.51% |
The entity has a beta of -0.34, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning SciVision Biotech are expected to decrease at a much lower rate. During the bear market, SciVision Biotech is likely to outperform the market. At this point, SciVision Biotech has a negative expected return of -0.45%. Please make sure to validate SciVision Biotech's standard deviation, jensen alpha, and the relationship between the coefficient of variation and information ratio , to decide if SciVision Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days SciVision Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 397.4 M | |
| Total Cashflows From Investing Activities | -77 M |
SciVision |
SciVision Biotech Relative Risk vs. Return Landscape
If you would invest 12,900 in SciVision Biotech on September 24, 2024 and sell it today you would lose (3,470) from holding SciVision Biotech or give up 26.9% of portfolio value over 90 days. SciVision Biotech is generating negative expected returns and assumes 2.3518% volatility on return distribution over the 90 days horizon. Simply put, 20% of stocks are less volatile than SciVision, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
SciVision Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SciVision Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SciVision Biotech, and traders can use it to determine the average amount a SciVision Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1927
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 1786 |
Estimated Market Risk
| 2.35 actual daily | 20 80% of assets are more volatile |
Expected Return
| -0.45 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average SciVision Biotech is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SciVision Biotech by adding SciVision Biotech to a well-diversified portfolio.
SciVision Biotech Fundamentals Growth
SciVision Stock prices reflect investors' perceptions of the future prospects and financial health of SciVision Biotech, and SciVision Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SciVision Stock performance.
| Return On Equity | 0.0952 | |||
| Return On Asset | 0.0331 | |||
| Profit Margin | 0.26 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 3.06 B | |||
| Shares Outstanding | 66.19 M | |||
| Price To Earning | 46.92 X | |||
| Price To Book | 2.47 X | |||
| Price To Sales | 6.56 X | |||
| Revenue | 505.54 M | |||
| EBITDA | 177.14 M | |||
| Cash And Equivalents | 508.81 M | |||
| Cash Per Share | 8.76 X | |||
| Total Debt | 300 M | |||
| Debt To Equity | 22.50 % | |||
| Book Value Per Share | 22.18 X | |||
| Cash Flow From Operations | 98.51 M | |||
| Earnings Per Share | 2.07 X | |||
| Total Asset | 2.26 B | |||
| Retained Earnings | 32 M | |||
| Current Asset | 657 M | |||
| Current Liabilities | 98 M | |||
About SciVision Biotech Performance
Evaluating SciVision Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if SciVision Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SciVision Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
SciVision Biotech Inc. manufactures and sells hyaluronic acid products in Taiwan. SciVision Biotech Inc.was founded in 2001 and is based in Kaohsiung, Taiwan. SCIVISION BIOTECH operates under Medical Instruments Supplies classification in Taiwan and is traded on Taiwan Stock Exchange.Things to note about SciVision Biotech performance evaluation
Checking the ongoing alerts about SciVision Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SciVision Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SciVision Biotech generated a negative expected return over the last 90 days | |
| About 38.0% of the company shares are owned by insiders or employees |
- Analyzing SciVision Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SciVision Biotech's stock is overvalued or undervalued compared to its peers.
- Examining SciVision Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SciVision Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SciVision Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SciVision Biotech's stock. These opinions can provide insight into SciVision Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for SciVision Stock Analysis
When running SciVision Biotech's price analysis, check to measure SciVision Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SciVision Biotech is operating at the current time. Most of SciVision Biotech's value examination focuses on studying past and present price action to predict the probability of SciVision Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SciVision Biotech's price. Additionally, you may evaluate how the addition of SciVision Biotech to your portfolios can decrease your overall portfolio volatility.